US Pat. No. 9,410,954

HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS

FOUNDATION MEDICINE, INC....

1. A method of treating a subject having a squamous cell carcinoma of the head and neck (HNSCC), comprising:
acquiring knowledge that the subject is positive for a human papillomavirus (HPV+); and
administering to the subject an anti-cancer agent other than a CDK inhibitor,
thereby treating the HNSCC in the subject.

US Pat. No. 9,707,703

APPARATUS, KITS AND METHODS FOR THE PRODUCTION OF BIOMIMETIC CONSTRUCTS

UCL BUSINESS PLC, London...

1. A method of producing a biomimetic construct comprising:
(i) introducing a gel solution to a well having an opening,
(ii) incubating the gel solution to form a gel,
(iii) introducing a porous plunger to the well,
(iv) compressing the gel with the porous plunger such that liquid is expelled from the gel through a surface of the gel that
is contacted by the porous plunger, the liquid, prevented from being expelled through the well bottom, entering the porous
plunger and the volume of the gel being reduced, thereby producing the biomimetic construct, wherein a volume of the liquid
expelled from the gel into the plunger per unit of surface area of the plunger that contacts the gel is about 2 mm to about
14 mm, and

(v) removing the porous plunger containing expelled liquid to leave said biomimetic construct in the well.
US Pat. No. 9,907,798

METHODS OF TREATING HEAD AND NECK CANCER

FOUNDATION MEDICINE, INC....

1. A method of treating a subject having a squamous cell carcinoma of the head and neck (HNSCC), the method comprising:
acquiring knowledge that the subject has a mutation in a cell-cycle gene; and
administering to the subject a cyclin dependent kinase (CDK) inhibitor that inhibits one or both of cyclin dependent kinase
4 (CDK4) or cyclin dependent kinase 6(CDK6),

thereby treating the HNSCC in the subject.

US Pat. No. 9,954,243

FUEL CELL COMPRISING AT LEAST TWO STACKED PRINTED CIRCUIT BOARDS WITH A PLURALITY OF INTERCONNECTED FUEL CELL UNITS

Imperial Innovations Limi...

1. A fuel cell comprising:a) at least two fuel cell boards, each of the fuel cell boards comprising at least one ion permeable membrane and a plurality of anodes and a plurality of cathodes, wherein the anodes and the cathodes are arranged in pairs such that each of the anodes is located on a side of the membrane opposite to one of the cathodes;
b) gas flow channels arranged between adjacent ones of the fuel cell boards for supplying an oxidisable gas to each of the anodes and a reducible gas to each of the cathodes; and
c) electrical connectors for connecting adjacent pairs of the anodes and the cathodes on the same one of the fuel cell boards;
wherein each of the fuel cell boards is arranged so that the anodes and the cathodes on one of the boards are located opposite to the anodes and cathodes, respectively, on an adjacent one of the boards;
wherein the membrane of each of the fuel cell boards is bonded to a multilayer Printed Circuit Board comprising a first current collection and distribution layer, a reactant distribution layer, and a second current collection and distribution layer; and
wherein the layers are bonded together to form the multilayer Printed Circuit Board.
US Pat. No. 9,897,619

ANALYTE EXTRACTION APPARATUS AND METHOD

Sphere Medical Limited, ...

1. A method of determining a concentration of a glycopeptide antibiotic containing a phenol moiety in a complex sample matrix,
the method comprising:
extracting the glycopeptide antibiotic from a metered portion of the complex sample matrix by:
exposing said metered portion of the complex sample matrix to an extraction material having an affinity with the glycopeptide
antibiotic; and

exposing the extraction material to a metered portion of a first eluent being a first organic solvent or a second eluent being
a second organic solvent/water mixture for releasing the glycopeptide antibiotic from the extraction material; and

determining a concentration of the glycopeptide antibiotic by:
adding an excess amount of Gibbs reagent (2,6 dichloroquinone-4-chloroimide) relative to the amount of the glycopeptide antibiotic
containing a phenol moiety to the metered portion of the first or second eluent;

activating the Gibbs reagent under alkaline conditions and, after the reaction between the activated Gibbs reagent and the
glycopeptide antibiotic has stabilized;

detecting the reaction product of the activated Gibbs reagent and the glycopeptide antibiotic in said metered portion of the
first or second eluent; and

determining a concentration of the glycopeptide antibiotic in the complex sample matrix from the detected reaction product,
said concentration being:

the concentration of unbound glycopeptide antibiotic in the complex sample matrix in case of the first eluent; or
the concentration of bound glycopeptide antibiotic in the complex sample matrix in case of the second eluent, and
wherein the step of exposing the extraction material to a metered portion of a first or second eluent is performed with the
first eluent and the concentration of the glycopeptide antibiotic in the complex sample matrix from the detected reaction
product is the concentration of unbound glycopeptide antibiotic in the complex sample matrix, the method further comprising
the step of exposing the extraction material to a metered portion of the second eluent and the concentration of the glycopeptide
antibiotic in the complex sample matrix from the detected reaction product is the concentration of bound glycopeptide antibiotic
in the complex sample matrix.

US Pat. No. 9,896,729

METHOD FOR DIAGNOSING A NEURODEGENERATIVE DISEASE

The University of Manches...

14. A method of diagnosing a subject as having or at increased risk of developing Frontotemporal Lobar Degeneration (FTLD)
or Motor Neuron Disease (MND)/Amyotrophic Lateral Sclerosis (ALS), the method comprising:
obtaining a sample from a subject;
mixing the sample with a labeled nucleic acid oligonucleotide having a nucleic acid sequence comprising SEQ ID NO: 7;
detecting in the C9orf72 gene the hybridization of the labeled nucleic acid oligonucleotide to the hexanucleotide repeat starting
at position 27,573,527 (coordinate taken from GRCh37/Hg19, forward strand), wherein increased binding of the nucleic acid
oligonucleotide is indicative of a subject having the hexanucleotide repeat and

diagnosing a subject as having or at increased risk for developing at least one of FTLD, MND/ALS, or a combination thereof,
when at least 30 hexanucleotide repeats are detected in a sample obtained from the subject.

US Pat. No. 9,044,528

ARTICLE AND METHOD OF SURFACE TREATMENT OF AN ARTICLE

UCL Business PLC, London...

1. An insert or implant comprising:
a substrate; and
over at least part of a surface of said substrate an outer coating of a biomaterial and an intermediate bonding layer bonded
to said substrate and to said outer coating, wherein a mechanical interlock is present between said intermediate bonding layer
and said outer coating, wherein said intermediate bonding layer has, in plan, first regions which are relatively thick and
second regions which are relatively thin, wherein said first and second regions form, in plan, a substantially regular pattern
and wherein the outer coating with intermediate bonding layer is able to support cellular attachment,

wherein adjacent first regions are between 5 ?m and 80 ?m apart,
wherein said intermediate bonding layer comprises TiO2, ZrO2, calcium titanate, a complex salt, Fe2O3, or a composite of the materials of the substrate and the outer coating,

wherein the biomaterial comprises hydroxyapatite,
and further wherein said intermediate bonding layer has through holes in it such that said outer coating is in contact with
said substrate as well as said intermediate bonding layer.

US Pat. No. 9,164,045

PHASE IMAGING

UCL BUSINESS PLC, London...

1. A method of phase imaging, comprising:
providing a source (2) of X-rays;

directing the source (2) of X-rays to define at least one X-ray beam with opposed first and second edges;

passing the at least one X-ray beam through a sample region of a sample onto an X-ray detector having pixels or rows of pixels
corresponding to the at least one X-ray beam;

obtaining a first image in a first configuration wherein the at least one X-ray beam includes at least one first X-ray beam
where the first edge but not the second edge of each first X-ray beam overlaps the corresponding pixel or row of pixels in
the X-ray detector and

obtaining a second image in a second configuration wherein the at least one X-ray beam includes at least one second X-ray
beam where the second edge but not the first edge of each second X-ray beam overlaps the corresponding pixel or row of pixels
in the X-ray detector to obtain a second X-ray image; and

obtaining a phase image from the first and second X-ray images by taking the difference between the first and second X-ray
images.

US Pat. No. 9,104,087

IMAGING APPARATUS AND METHODS

UCL Business PLC, London...

1. A method of scanning a target volume with a beam of electromagnetic radiation, said method comprising:
passing said electromagnetic radiation through a first acousto-optic deflector and a second acousto-optic deflector downstream
of said first acousto-optic deflector, the deflectors containing first and second acoustic waves respectively so as to move
a focus position of said beam along a scan path in said target volume;

wherein said first and second acoustic waves are chirped to have a constantly increasing or decreasing frequency; and
when one of said acoustic waves is at a predetermined maximum or minimum frequency value, offsetting the frequency of each
acoustic wave such that the acoustic waves may continue to be chirped while having frequencies lower than said predetermined
maximum frequency and higher than said predetermined minimum frequency.

US Pat. No. 9,597,211

PROSTHESIS DELIVERY SYSTEM

UCL Business PLC, London...

1. A prosthesis delivery system comprising:
a sheath defining an axial direction;
a plurality of tethers movable axially relative to the sheath;
a holder movable axially within the sheath, wherein the holder is a single tube configured to constrain radially the plurality
of tethers; and

a collapsible prosthesis that is attached to at least one of the plurality of tethers, the collapsible prosthesis comprising
a support structure comprising a plurality of apexes, wherein each tether in the plurality of tethers passes through a plurality
of the apexes, and further wherein the prosthesis delivery system is configured to deliver the prosthesis to a target position
in a living being.

US Pat. No. 9,192,901

CO-CURRENT MIXER, APPARATUS, REACTOR AND METHOD FOR PRECIPITATING NANOPARTICLES

UCL BUSINESS PLC, London...

1. A method of precipitating nanoparticles in a continuous hydrothermal or solvothermal process by the mixing of a precursor,
which consists essentially of an aqueous solution or suspension of solid particles for the production of nanoparticles, with
a fluid for the production of nanoparticles, the fluid containing water or a mixture of water and solvents other than water
and being substantially at or above the critical point of the fluid in a co-current mixer having unidirectional flow from
coaxial inner and outer inlets to an outlet via a mixing zone immediately downstream of said inlets, the method comprising
the steps of:
providing a fluid flow of the precursor to the outer inlet,
providing a fluid flow of the fluid to the inner inlet, and
precipitating nanoparticles by mixing of the precursor with the fluid in said mixing zone.

US Pat. No. 9,427,396

MAGNETIC MICROBUBBLES, METHODS OF PREPARING THEM AND THEIR USES

UCL Business PLC, London...

1. A method of preparing a suspension of microbubbles for use in a carrier liquid, wherein the microbubbles have a gas core
and a liquid shell, said liquid shell comprising magnetic nanoparticles, and wherein the method comprises the steps of:
(a) determining a size of the shell relative to the gas core and an amount of the nanoparticles in the shell of a microbubble
that satisfy the following conditions:

(i) a force due to buoyancy (FBW) of the microbubble in the carrier liquid is greater than a weight (W) of the microbubble;

(ii) a magnetic force (FM) on the microbubble due to a magnetic field applied to the carrier liquid is greater than a combination of the weight (W)
and the force due to buoyancy (FBW) of the microbubble;

(iii) said magnetic force (FM) on the microbubble is greater than a force due to viscous drag (FD) on the microbubble due to flow of the carrier liquid; and

(iv) a scattering cross section (?scat) of the microbubble to ultrasound allows the microbubble to be detectable and rupturable on exposure to ultrasound;

(b) using the amount of nanoparticles in the shell and the relative size of the shell to the gas core of the microbubble to
determine the amount of the magnetic nanoparticles and the amount of liquid for the shell needed to prepare a suspension of
the microbubbles; and

(c) preparing a suspension of the microbubbles using the amount of the magnetic nanoparticles and the amount of liquid for
the shell needed to prepare the suspension.

US Pat. No. 9,186,414

COMPOSITION FOR INTRAOCULAR IMPLANTATION OF BEVACIZUMAB

UCL Business PLC, London...

1. A solid, compressed pharmaceutical composition comprising i) a peptide active pharmaceutical ingredient, ii) a polysaccharide
excipient, and iii) an oligosaccharide excipient, wherein the polysaccharide excipient is present in the form of a potassium
salt thereof.

US Pat. No. 9,255,008

GRAPHENE SOLUTIONS

UCL Business PLC, London...

1. A solution of graphenes, comprising dissolved graphenes at a concentration of at least 1 mg/ml and a polar aprotic solvent,
wherein the graphene is in the form of individual graphene monolayers, and/or wherein monolayer, unscrolled, and unfolded
graphenes comprise 80 vol % or more of the graphene species present in solution, as measured by small angle neutron scattering
(SANS).
US Pat. No. 9,101,693

CELL-INDEPENDENT FABRICATION OF TISSUE EQUIVALENTS

UCL BUSINESS PLC, London...

1. A method of producing a biomaterial comprising viable mammalian cells, wherein the method comprises:
providing a gel comprising a matrix of fibers and a liquid, said liquid being interstitial to the matrix of fibers, and the
interstitial liquid containing viable mammalian cells, wherein said gel is produced by polymerisation of monomers dissolved
in liquid containing viable mammalian cells; and,

applying an external compaction to the gel to expel 50% to 99.9% of the interstitial liquid from the gel, thereby causing
compaction of the gel,

thereby producing a biomaterial comprising viable mammalian cells.

US Pat. No. 10,087,144

AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE

UCL Business PLC, London...

1. A compound of formula (1), a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof:
wherein
V is N or CR3;
X is N or CR4;
Y is N or CR5;
Z is N or CR6;
B is —(C?O)R1;
R1 is a proteinogenic ? amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the ? amino group, which amino acid is optionally esterified at the ? carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group;
W is CR8;
R8 and R9 together form a bond;
R2 is -L?-A2 group;
R3 is a hydrogen atom, a halogen atom, or a hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, nitro, or —NR?R? group, wherein R? and R? are the same or different and each represent a hydrogen atom or C1-C6 alkyl group;
R4 and R5 are the same or different and each represent a hydrogen atom, a halogen atom, or a hydroxyl, C1-C8 alkyl, C1-C8 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, —NR?R?, —CO2R??, C6-C10 aryl, 5- to 10-membered heteroaryl, 5 to 10-membered heterocyclyl, or —CO—(C1-C6 alkyl) group, wherein R?, R? and R?? are the same or different and each represent a hydrogen atom or C1-C6 alkyl group, or R4 and R5 and the carbon atoms bonded to R4 and R5 together form a 5- to 6-membered heterocyclic ring;
R6 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or —CO2R? group, wherein R? is hydrogen or C1-C6 alkyl;
R7 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl, or C1-C6 haloalkyl group;
A2 is a C6-C10 aryl or 5- to 10-membered heteroaryl group; and
L? is a C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene group;
wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl independently is unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, —SOR, —SO2R, —NR?R?, —NR?(C?O)R?, —COOR, nitro or cyano substituents, wherein R, R? and R? are the same or different and each represents a hydrogen atom or C1-C4 alkyl group.

US Pat. No. 9,804,256

APPARATUS AND METHOD FOR DETERMINING THE LOCATION OF A MOBILE DEVICE USING MULTIPLE WIRELESS ACCESS POINTS

UCL BUSINESS PLC, London...

1. A method of determining the location of a mobile device using multiple wireless access points, each wireless access point
comprising multiple antennas, said method comprising:
receiving a communication signal from the mobile device at said multiple antennas of said multiple wireless access points;
for each wireless access point, determining angle-of-arrival information of the received communication signal at the wireless
access point, based on a difference in phase of the received signal between different antennas;

collecting, from each of the multiple wireless access points, the determined angle-of-arrival information for the received
communication signal from the mobile device;

estimating the location of the mobile device from the collected angle-of-arrival information;
discriminating against multipath reception of the communication signal at a wireless access point, wherein at least one wireless
access point comprises two sets of antennas for discriminating against multipath reception; and

discriminating in favour of a direct path over a multipath by:
using the two sets of antennas at the wireless access point to disambiguate a direct path from the wireless access point to
the mobile device from a multipath, based on intra-wireless access point triangulation between the two sets of multiple antennas;

determining a difference in angle of arrival for each component of the received communication signal at each of said two sets
of antennas;

determining a source distance for each component of the received communication signal based on said difference in angle; and
identifying the direct path as corresponding to the component of communication signal having the shortest source distance.

US Pat. No. 9,343,874

SEMICONDUCTOR DEVICE AND FABRICATION METHOD

UCL BUSINESS PLC, London...

1. A semiconductor device comprising:
a silicon substrate;
an epilayer formed on the silicon substrate; and
at least one layer of III-V compound directly on the epilayer,
wherein the epilayer comprises a compound of the formula:
Al1-x[X]xAs
wherein:
X is at least one group III element other than Al;
x is greater than or equal to 0; and
x is less than or equal to 0.5,
wherein the at least one layer of III-V compound directly on the epilayer is one of a GaAs layer, an InP layer or a GaSb layer.

US Pat. No. 9,069,227

METHODS AND APPARATUS TO CONTROL ACOUSTO-OPTIC DEFLECTORS

UCL BUSINESS PLC, London...

1. An acousto-optic lens comprising:
a first acousto-optic deflector arranged to support a first acoustic wave;
a second acousto-optic deflector arranged to support a counter-propagating second acoustic wave;
a driver for synthesizing first and second drive signals for said respective first and second acousto-optic deflectors;
wherein said driver is arranged to synthesize a first drive signal that is phase-modulated by a non-sinusoidal first function
that is capable of being expressed as a Taylor series having one or more coefficients greater than second order;

wherein said driver is arranged to synthesize a second drive signal that is phase-modulated by a non-sinusoidal second function
that is capable of being expressed as a Taylor series having one or more coefficients greater than second order; and

wherein said acousto-optic lens further comprises:
a memory for storing drive parameters associated with respective focal positions in space, wherein said acousto-optic lens
is arranged to use said stored drive parameters when it is intended to focus electromagnetic radiation at a respective position
in space.

US Pat. No. 9,493,460

DIIMIDE COMPOUNDS

UCL BUSINESS PLC, London...

1. A compound of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof

wherein m, n, p and q are each independently selected from integers 2 or 3; and
wherein X1 and X2 are N-methyl piperazine and Y1 and Y2 are morpholino or X1 and X2 are morpholino and Y1 and Y2 are N-methyl piperazine.

US Pat. No. 10,591,496

ANALYTE EXTRACTION APPARATUS AND METHOD

Sphere Medical Limited, ...

1. An apparatus for automatically extracting of a glycopeptide antibiotic containing a phenol moiety from a complex sample matrix comprising cellular material, the apparatus comprising:a sample reception stage having an output for providing a defined quantity of the complex sample matrix;
a mixing stage having a first input in fluidic connection with the output of the sample reception stage, a second input for receiving a lysing agent and an output for providing a mixture of the defined quantity of the complex sample matrix and the lysing agent;
a delay stage having an input in fluidic connection with the output of the mixing stage and an output for providing a delayed mixture of the defined quantity of the complex sample matrix and the lysing agent;
a filtering stage comprising a sorbent material for mechanically lysing the cellular material, said sorbent material having an affinity for binding of the glycopeptides antibiotic, said filtering stage having an input in fluidic connection with the output of the delay stage; and
a controller for controlling the flow rate of the mixture of the defined quantity of the complex sample matrix and the lysing agent through said delay stage, wherein the apparatus further comprises a colorimetric measurement stage in fluid connection with the filtering stage and arranged to determine the colorimetric spectrum of an eluent received from the filtering stage including a reaction product of the glycopeptide antibiotic and the activated Gibbs reagent; and
a processor coupled to the colorimetric measurement stage adapted to derive a concentration of the glycopeptide antibiotic in the complex sample matrix from a specific wavelength in the range of 580-600 nm.

US Pat. No. 9,837,091

AUDIO-VISUAL DIALOGUE SYSTEM AND METHOD

UCL Business PLC, (GB)

1. An audio-visual dialogue system, comprising:
an audio input device;
an audio output device;
a visual output device; and
a processor, the processor being arranged to:
receive an input audio signal representing a source voice from the audio input device;
perform substantially real-time voice conversion on the input audio signal to produce an output audio signal representing
a target voice, wherein the output audio signal is provided to the audio output device, and wherein the real-time voice conversion
process includes:

i) decomposing the input audio signal into a set of time-varying filter characteristics and a residual excitation signal;
ii) spectrally transforming the time-varying filter characteristics, and/or modifying a pitch of the residual excitation signal;
and

iii) synthesising the output audio signal in dependence on the transformed time-varying filter characteristics and/or the
pitch modified residual excitation signal;

generate an avatar, wherein the avatar is visually displayed on the visual output device; and
facially animate the generated avatar, wherein the animation is synchronised with the output audio signal,
wherein the processor is further arranged to customise the real-time voice conversion including
1) selecting one of a plurality of predefined target voices, wherein the predefined target voices are represented by a set
of respective linear transformations which include a set of time-varying filter characteristics and a pitch scaling factor
and

2) adjusting the transformation time-varying filter characteristics and/or the pitch scaling factor of the selected predefined
target voice to give customised target voice parameters,

wherein transform vectors of the set of linear transformations are reduced to a mean transform vector and a plurality of orthogonal
change vectors and a user interface control is used to adjust a change amount by which a change vector is added into the mean
transform vector such that the time-varying filter characteristics are adjusted.

US Pat. No. 9,347,884

MICROFLUIDIC DEVICE WITH DIRECT SAMPLE HEATING VIA ELECTROMAGNETIC RADIATION

UCL BUSINESS PLC, London...

1. A microfluidic device, for analysis, comprising:
a chip comprising a channel having a cross sectional area with a width less than or equal to 150 ?m and a depth less than
or equal to 150 ?m;

a first source of radiation comprising a light emitting diode or a laser which emits electromagnetic radiation having a wavelength
of 1400 nm to 1600 nm for directly heating a sample placed in the channel in use; and

an analytical assembly configured to record a change in the sample arising from heating of the sample with the first source
of electromagnetic radiation;

wherein the first source of electromagnetic radiation comprises multiple sources of electromagnetic radiation or a single
source of electromagnetic radiation arranged so that the electromagnetic radiation is directed along the length of the channel,
such that the sample is heated uniformly across the cross-sectional area of the channel and along the length of the channel.

US Pat. No. 9,340,418

METHOD FOR DISPERSING AND SEPARATING NANOTUBES WITH AN ELECTRONIC LIQUID

UCL Business PLC, London...

1. A method for dispersing carbon nanotubes, comprising contacting the nanotubes with an electronic liquid comprising a metal,
and an amine solvent,
wherein the contacting is performed under such conditions that a solution of individual carbon nanotubes is produced, and
wherein the metal is included in the electronic liquid in an amount such that the ratio of metal atoms in the electronic liquid
to carbon atoms in the carbon nanotubes with which the electronic liquid is contacted is about 1:6 or less.

US Pat. No. 9,171,650

X-RAY IMAGING

UCL BUSINESS PLC, London...

1. A method of aligning at least one mask in an X-ray imaging apparatus in at least one translational and/or rotational direction
of the at least one mask, the mask having a plurality of apertures, the method including:
(a) directing X-rays from a source (2) in a z-direction through the mask to the X-ray detector orientated perpendicularly to the X-rays, the X-ray detector having
pixels arranged in an x-direction and in a perpendicular y-direction;

(b) for each of a plurality of potential alignment positions in at least one of the translational and/or rotational directions,
translating the mask in the x- or y-direction with respect to the X-ray detector to a plurality of translational position
increments, identifying for pixels in the detector the translational position increment corresponding to an extremum of the
detected intensity profile for that pixel, and hence identifying steps in a predetermined function which separates the regions
of the detector that have the same position of the extremum for all pixels in that area;

(c) selecting the alignment position in which the steps in the identified translational position increment over the two-dimensional
area of the pixel detector are minimised and/or aligned with the x- and y-directions, and

(d) moving the mask to the selected alignment position.

US Pat. No. 10,174,094

REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES

UCL Business Plc, London...

1. A compound of formula (IIIa)wherein:R1 is an antibody or antibody fragment that is capable of binding to a specific antigen via an epitope on the antigen, said antibody or antibody fragment containing a first cysteine residue and a second cysteine residue;
R1 is attached at the 2-position in the compound of formula (IIIa) by a thiol bond —S— which corresponds to the thiol group in said first cysteine residue;
R1 is attached at the 3-position in the compound of formula (IIIa) by a thiol bond —S— which corresponds to the thiol group in said second cysteine residue;
F2 is a drug; and
L represents a linker group.
US Pat. No. 9,539,203

PHARMACEUTICAL COMPOSITION COMPRISING A VITAMIN E DERIVATIVE AND A CELL DEATH MARKER

UCL BUSINESS PLC, London...

1. A pharmaceutical composition, comprising: a combination of a Vitamin E derivative and a cell death marker, wherein the
cell death marker is annexin V or a functional fragment or derivative thereof that binds reversibly to cellular membranes
in the presence of cations.
US Pat. No. 9,447,168

NUCLEIC ACID MOLECULES ENCODING MODIFIED FACTOR VIII PROTEINS

UCL BUSINESS PLC, London...

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a Factor VIII protein, wherein the Factor VIII
protein B domain spacer is replaced and the B domain comprises the amino acid sequence of SEQ ID NO: 4, and wherein the Factor
VIII protein participates in blood coagulation via the coagulation cascade.

US Pat. No. 10,115,201

APPARATUS AND METHOD FOR GENERATING AND USING A SUBJECT-SPECIFIC STATISTICAL MOTION MODEL

UCL Business PLC, London...

1. A method for building a subject-specific statistical model of shape variation for an anatomical structure, the method comprising:providing a set of geometric representations of shape for said anatomical structure, wherein each representation is associated with one of multiple subjects, each subject having a respective subset of associated representations, and each subset comprising multiple representations including a reference representation, said multiple representations corresponding to different shapes of the anatomical structure arising from physical motion and/or deformation thereof, the method comprising:
specifying a set of shape parameters whose values, for any given representation, characterise the shape of the representation;
for each subject, representing a probability distribution of the values of the shape parameters across the subset of representations associated with that subject by a set of subject-specific distribution parameters;
determining a regression between the subject-specific distribution parameters and the respective reference representation for each subject;
applying said determined regression to a reference representation for a new subject to determine subject-specific distribution parameters for the new subject; and
using the subject-specific distribution parameters to build a subject-specific statistical motion model for the new subject.

US Pat. No. 9,619,890

SYSTEM AND METHOD FOR ANNOTATING IMAGES BY PROPAGATING INFORMATION

UCL BUSINESS PLC, London...

1. A computer-implemented method of annotating images in a data set comprising a first set of images which initially have
annotations and a second set of images which initially do not have annotations, the method comprising:
determining spatial correspondences for all pairs of images in the data set, wherein each spatial correspondence represents
a mapping of a location in a first image to a corresponding location in a second image, including determining a first mapping
of a first location in the first image to a first location in the second image and a second mapping of a second location in
the first image to a second location in the second image, wherein the first location in the first image is different from
the second location in the first image, and the first location in the second image is different from the second location in
the second image;

for each mapping, calculating a connection strength between the location in the first image and the corresponding location
in the second image, wherein the connection strength is determined using a pairwise measure of similarity between one or more
features in a pair of images that is calculated locally on a restricted portion of the pair of images, such that the connection
strength is spatially variant across a pair of images, including calculating a first connection strength for said first mapping
and a second connection strength for the second mapping, wherein the first connection strength for the first mapping is different
from the second connection strength for the second mapping; and

iteratively propagating information across images in the data set using: (i) the connection strengths of the mappings, including
the first and second connection strengths of the first and second mappings respectively, and (ii) an estimate of the accuracy
of the information which is being propagated, as weights for propagating the information, wherein the propagated information
is used to provide annotations to images which do not initially have annotations, and wherein each iteration performs a propagation
across all images in the data set.

US Pat. No. 9,401,404

SEMICONDUCTOR DEVICE AND FABRICATION METHOD

UCL BUSINESS PLC, London...

1. A method of fabricating a semiconductor heterostructure of gallium arsenide on germanium comprising the steps of:
protecting a surface comprising germanium by a shutter covering the surface in an environment having a partial pressure of
arsenic that is less than 10?8 torr;

epitaxially growing a layer of gallium on the surface immediately after opening the shutter to expose the surface; and
epitaxially growing a layer of gallium arsenide on the gallium covered surface;
wherein the shutter is positioned directly covering the surface to keep the surface substantially free of arsenic prior to
the step of epitaxially growing a layer of gallium;

wherein said germanium surface is a (001) oriented germanium substrate off-cut by between 1° and 6° towards the [110] direction,
wherein a further heterostructure comprises at least one quantum dot on a substrate comprising a germanium layer or germanium-silicon
alloy layer on a silicon substrate; and

wherein the quantum dot is between an upper cladding layer and guiding layer and a lower cladding layer and guiding layer.

US Pat. No. 9,079,775

METHOD FOR SEPARATING NANOMATERIALS

UCL Business PLC, London...

1. A method for dispersing carbon nanotubes to produce a solution of dispersed, charged individual carbon nanotubes, comprising
an electrochemical process,
wherein the electrochemical process involves the transfer of a charged species between an electrode and an electrolyte,
wherein the method further comprises applying a potential between a working electrode and a counter electrode,
wherein the working electrode comprises carbon nanotubes,
wherein the working electrode and counter electrode form part of an electrochemical cell that further comprises the electrolyte
and

wherein the potential is applied so as to dissolve at least some of the carbon nanotubes of the working electrode and to disperse
these carbon nanotubes as charged individual carbon nanotubes in solution.

US Pat. No. 9,559,431

ANTENNA CONFIGURATION FOR USE IN A MOBILE COMMUNICATION DEVICE

UCL BUSINESS PLC, London...

1. An antenna configuration for use in a mobile telecommunications device to provide three-dimensional, orthogonal polarisation,
said antenna configuration comprising:
a half mode substrate integrated waveguide (HMSIW) antenna comprising two parallel conductive plates separated by a dielectric,
said HMSIW antenna having a substantially rectangular shape comprising a first edge, a second edge perpendicular to the first
edge and connected to the first edge by a first corner, a third edge opposing and parallel to the first edge and connected
to the second edge by a second corner, and a fourth edge opposing and parallel to the second edge and connected to the first
edge by a third corner and to the third edge by a fourth corner, wherein the first and second edges are open for radiation;

a first slot antenna including a first dielectric strip extending from the third corner in a direction which is parallel to
and collinear with the first edge and away from the first corner; and

a second slot antenna including a second dielectric strip extending from the second corner in a direction which is parallel
to and collinear with the second edge and away from the first corner;

wherein said two parallel plates of the HMSIW antenna lie in a plane defined by the first and second dielectric strips, and
wherein the first slot antenna is responsible for linear polarisation in a direction parallel to the first edge, the second
thick-slot antenna is responsible for linear polarisation in a direction parallel to the second edge, and the HMSIW antenna
is responsible for linear polarisation in a direction perpendicular to the parallel conductive plates of the HMSIW antenna.

US Pat. No. 10,475,994

OXIDE MEMORY RESISTOR INCLUDING SEMICONDUCTOR NANOPARTICLES

UCL Business PLC, London...

1. A memory resistor having an on state and an off state, comprising:(a) a first electrode;
(b) a second electrode; and
(c) an inhomogeneous dielectric layer disposed between the first and second electrodes, wherein the dielectric layer comprises an inhomogeneous dielectric material having multiple domains comprising column structures;
wherein the dielectric layer further comprises amorphous nanoparticles of semiconductor material, and wherein in the on state the nanoparticles form at least one conductive filament encapsulated by the dielectric layer, thereby providing a conductive pathway between the first electrode and the second electrode, wherein the at least one conductive pathway is formed at least in part along a boundary between two of said domains;
wherein the memory resistor is configured to be taken from the off state to the on state when a set voltage is applied in a set process;
wherein the on state is low resistance and the off state is high resistance; and
wherein the memory resistor is configured to return from the on state to the off state when a reset voltage is used to produce a current in a reset process.
US Pat. No. 10,391,145

COMBINED USE OF A VECTOR ENCODING A MODIFIED RECEPTOR AND ITS EXOGENOUS AGONIST IN THE TREATMENT OF SEIZURES

UCL BUSINESS PLC, London...

1. A method of treating a seizure disorder, which is focal epilepsy, in a patient suffering from said disorder,wherein either
(a) said patient has previously been administered a vector encoding a modified receptor,
wherein the modified receptor is a human muscarinic acetylcholine receptor M4, which is a Gi protein-coupled receptor (GPCR), coupled via a Gi-protein to a G protein-coupled inwardly rectifying potassium channel (GIRK), and
wherein the modified receptor is characterised by (i) a decreased responsiveness to its endogenous activating ligand and/or (ii) a retained or enhanced responsiveness to an exogenous agonist, or
(b) administering to the patient said vector,
wherein the modified receptor is encoded by a nucleic acid operably linked to a neuronal cell type-specific promoter such that said modified receptor is expressed in excitatory neurons of a seizure focus in brain of the patient;
which method comprises subsequently administering to said patient an exogenous agonist selected from clozapine, clozapine-N-oxide and perlapine,whereby the presence of said agonist in the brain of the patient activates said modified receptor,whereby activation of said modified receptor reversibly inhibits the excitability of, and neurotransmission by, the excitatory neurons in the seizure focus.

US Pat. No. 10,226,298

SYSTEM AND METHOD FOR COMPUTER-ASSISTED PLANNING OF A TRAJECTORY FOR A SURGICAL INSERTION INTO A SKULL

UCL Business PLC, London...

1. A method of using a computer system to assist in planning a trajectory for a surgical insertion into a skull, the method comprising:providing the computer system with a three-dimensional representation of the skull and of critical objects located within the skull, wherein said critical objects comprise anatomical features to be avoided during the surgical insertion;
providing the computer system with a target location for the insertion within the skull;
selecting an entry point representing a surface location on the skull;
determining by the computer system for the entry point an associated trajectory from the entry point to the target location;
calculating by the computer system a risk factor for said entry point by integrating f(x) along the trajectory associated with the entry point, where x represents distance along the trajectory to a sample point, and f(x) is a function based on distance from the sample point at distance x to a critical object which is nearest to said sample point;
wherein selecting an entry point comprises generating by the computer system a plurality of entry points, each entry point representing a surface location on the skull, each entry point being associated with a trajectory from the entry point to the target location, and wherein said step of assessing is performed for each of said plurality of entry points; and
wherein the step of generating produces a first set of entry points, and the step of assessing is performed with respect to a second, reduced set of entry points, and the method further comprises discarding by the computer system entry points from the first set to form the second set, wherein an entry point is discarded from the first set of entry points if the entry point has an entry angle which fails a condition for being substantially perpendicular to the skull surface.
US Pat. No. 10,172,885

CELL

UCL BUSINESS PLC, London...

1. A T cell or natural killer (NK) cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising:(i) an antigen-binding domain;
(ii) a spacer
(iii) a trans-membrane domain; and
(iv) an endodomain,wherein the antigen binding domains of the first and second CARs bind to different antigens;wherein one of the first or second CARs is an activating CAR comprising an Immunoreceptor Tyrosine-based Activation motif (ITAM)-containing activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-on inhibitory endodomain comprising a tyrosine phosphatase domain from a Src homolog (SH2) domain-containing protein tyrosine phosphatase which is recruited by a phosphorylated Immunoreceptor Tyrosine-based Activation motif (ITIM); and wherein the spacer of the first CAR and the spacer of the second CAR co-localise upon ligation of the first CAR and the second CAR.
US Pat. No. 9,844,568

POROUS CARBON PARTICLES FOR USE IN THE TREATMENT OR PREVENTION OF LIVER DISEASE

UCL Business PLC, London...

1. A method of treating liver disease or preventing progression of liver disease to cirrhosis and its complications, comprising:
administering an effective amount of porous carbon particles wherein 20% to 90% of a total pore volume of the porous carbon
particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume
is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the porous carbon particles are administered orally
or rectally.

US Pat. No. 9,399,016

MATERIALS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIALS TO CELLS

UCL BUSINESS PLC, London...

1. A non-viral delivery complex, for delivering genetic material when combined with a nucleic acid, that comprises:
(i) a peptide of formula A-B-C wherein
A is a polycationic nucleic acid-binding component,
B is a spacer element peptide that is susceptible to cleavage within a cell, and
C is a cell surface receptor binding component,
wherein B, the spacer element peptide comprises amino acid sequences susceptible to cleavage by furin selected from RX1KR [SEQ ID NO: 2] and RX2RR [SEQ ID NO: 3] in which X1 and X2 which may be the same or different and each represent any amino acid residue, or comprises amino acid sequences susceptible
to cleavage by cathepsin selected from X3X4 in which X3 is selected from Tyrosine (Tyr, Y), Phenylalanine (Phe, F), Leucine (Leu, L), Valine (Val, V) and Isoleucine (Ile, I) and
X4 is selected from Glycine (Gly, G), Alanine (Ala, A) and Glutamic acid (Glu, E);

and wherein C, the cell surface receptor binding component, comprises a peptide sequence selected from:
RGD;
RRETAWA [SEQ ID NO: 5];
LDV;
X5SM in which X5 is a basic amino acid residue;

LX6HK [SEQ ID NO: 6] in which X6 is Q or P;

PSGX7ARA [SEQ ID NO: 7] in which X7 is A or T;

SX8RSMNF [SEQ ID NO: 8] in which X8 is an acidic amino acid residue;

LX9HKSMP [SEQ ID NO: 9] in which X9 is P or Q;

PX10X11X12T [SEQ ID NO: 19] in which X10, X11 and X12, which may be the same or different, each represents an amino acid residue;

PSX13S [SEQ ID NO: 20] in which X13 represents an amino acid residue;

QX14X15X16Q [SEQ ID NO: 21] in which X14 and X16, which may be the same or different, each represents an amino acid residue, and X15 represents an amino acid residue having an amide side chain; and

SX17S in which X17 represents an amino acid residue having an aliphatic side chain; and

(ii) a lipid of formula (III):

wherein:
each Y is the same or different and is selected from —O—, and —O—C(O)—;
each R4 is the same or different and is selected from a straight or branched, saturated or unsaturated C7-24 hydrocarbyl group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen and OR?,
wherein R? is a C1-6 hydrocarbyl group;

each R5 is the same or different and is selected from a straight or branched, saturated or unsaturated C1-10 hydrocarbyl group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen, —OR?,
—C(O)OH, —CN, —N(R?)2, and —C(O)R?, wherein each R? is the same or different and is a C1-6 hydrocarbyl group;

Sp is a C1-8 alkylene group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen and OR?, wherein
R? is a C1-6 hydrocarbyl group;

W is selected from —O—C(O)—, —C(O)O—, and the group of formula (IV):

n denotes the number of chains, and n=1 if the linker W is —O—C(O)— or —C(O)O—, and n=2 if the linker W is the group of formula
(IV);

each B is the same or different and is a C1-6 alkylene group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen, —OR1, —C(O)OH, —CN, —NR1R2, —C(O)OR1, —OC(O)R1 and —C(O)R1;

R1 and R2 are the same or different and are C1-4 hydrocarbyl;

m is an integer from 1 to 100; and
Q is selected from —N+(R3)3, —OH, and —OR3 wherein R3 is an unsubstituted C1-4 alkyl group or a trifluoromethyl group.

US Pat. No. 9,393,323

OPTIMISED CODING SEQUENCE AND PROMOTER

UCL BUSINESS PLC, London...

1. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 80% homology to the nucleotide sequence
of SEQ ID NO: 1 and which encodes functional factor VIII protein and wherein with respect to the amino acid sequence encoded
by SEQ ID NO: 1 any amino acid change encoded by the isolated nucleic acid molecule is in the portion of the amino acid sequence
which replaced the B domain of the factor VIII protein.

US Pat. No. 10,234,467

APPARATUS AND METHOD FOR TESTING MEDICAMENTS

UCL Business PLC, London...

1. A method of testing the solubility and/or dissolution of a medical dosage form by means of apparatus which includes a chamber for holding a solvent medium and a dosage form for testing; a sensing device for sensing a parameter derivable from the chamber, the parameter being indicative of dissolution of a medical dosage form; a pH probe disposable in the chamber for measuring the pH of solvent medium in the chamber; a first valve coupling connectable to a supply of pH reducing fluid, the first valve coupling including a first conduit feeding into the chamber; a second valve coupling connectable to a supply of pH increasing fluid, the second valve coupling including a second conduit feeding into the chamber; and a control device connected to the probe and to the first and second valve couplings and operable to control the supply of pH increasing and pH reducing fluid into the chamber on the basis of the determined pH within the chamber; the method including the steps of:providing in the chamber a solvent, the solvent being a bicarbonate based medium;
providing in the chamber at least one dosage form to be tested;
monitoring for the dissolution of the dosage form; and
monitoring the pH of the solution and adjusting the pH of the solvent in the chamber by supplying one or both of the pH reducing and the pH increasing fluids.

US Pat. No. 9,295,729

REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES

UCL Business Plc, London...

1. A method for linking a compound of formula F1—H, wherein F1 is a first functional moiety which, together with the H-atom to which it is attached, contains an SH group, to a second functional
moiety of formula F2 with a reagent which is a compound of formula (Ia):
wherein:
X and X? each represent oxygen;
either:
R3 and R3? together form a group of formula —N(R33?), wherein R33? represents a hydrogen atom or a group of formula Y, Nu,

-L(Z)n or IG; or

R3 and R3? together form a group of formula —N(R33?)—N(R33?)—, wherein each R33? is the same or different and represents a hydrogen atom or a group of formula Y, Nu, -L(Z)n or IG;

R2 represents a hydrogen atom or a group of formula Y, Nu, -L(Z)n or IG;

each group of formula Y is the same or different and represents an electrophilic leaving group;
each group of formula Nu is the same or different and represents a nucleophile selected from —OH, SH, —NH2 and —NH(C1-6 alkyl);

each group of formula L is the same or different and represents a linker group;
each group of formula Z is the same or different and represents a reactive group attached to a group of formula L which is
capable of reacting with a compound containing a second functional moiety such that said second functional moiety becomes
linked to said group of formula L;

n is 1, 2 or 3; and
each group of formula IG is the same or different and represents a moiety which is a C1-20 alkyl group, a C2-20 alkenyl group or a C2-20 alkynyl group, which is unsubstituted or substituted by one or more substituents selected from halogen atoms and sulfonic
acid groups, and in which (a) 0, 1 or 2 carbon atoms are replaced by groups selected from C6-10 arylene, 5- to 10-membered heteroarylene, C3-7 carbocyclylene and 5- to 10-membered heterocyclylene groups, and (b) 0, 1 or 2 —CH2— groups are replaced by groups selected from —O—, —S—, —S—S—, —C(O)— and —N(C1-6 alkyl)- groups, wherein:

(i) said arylene, heteroarylene, carbocyclylene and heterocyclylene groups are unsubstituted or substituted by one or more
substituents selected from halogen atoms and C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthiol, —N(C1-6 alkyl)(C1-6 alkyl), nitro and sulfonic acid groups; and

(ii) 0, 1 or 2 carbon atoms in said carbocyclylene and heterocyclylene groups are replaced by —C(O)-groups;
and
either:
the first functional moiety or the second functional moiety is a protein which is an antibody or antibody fragment, and the
other of the first functional moiety and the second functional moiety is a drug; or

the first functional moiety or the second functional moiety is a polymeric moiety selected from peptides, proteins, polysaccharides,
polyethers, polyamino acids, polyvinyl alcohols, polyvinylpyrrolidones, poly(meth)acrylic acid, polyurethanes and polyphosphazenes,
and the other of the first functional moiety and the second functional moiety is a drug;
wherein the method comprises attaching the F1 to the compound of formula (Ia) via nucleophilic attack of the SH group in the compound of formula F1—H at the 2-position of the compound of formula (Ia), such that the group Y at the 2-position is replaced by the group F1; and the method comprises attaching F2 by electrophilic addition across the carbon-carbon double bond between the 2- and 3-positions of the compound of formula (Ia)
or by reaction with a reactive group on the compound of formula (Ia) that is capable of reacting with F2.

US Pat. No. 10,363,015

METHOD AND APPARATUS FOR DETERMINING THE LOCATION OF A MEDICAL INSTRUMENT WITH RESPECT TO ULTRASOUND IMAGING, AND A MEDICAL INSTRUMENT TO FACILITATE SUCH DETERMINATION

UCL BUSINESS PLC, London...

1. An ultrasound system comprising:an ultrasound unit including an ultrasound probe for acquiring an anatomical image of a human body and for locating a medical instrument with respect to said anatomical image, the ultrasound probe including a first set of imaging transducer elements and a second set of localisation transducer elements, wherein the first set of imaging transducer elements are distinct and disjoint from the second set of localisation transducer elements, wherein: the first set of imaging transducer elements are configured to: (i) produce ultrasound imaging transmissions into the human body, wherein the ultrasound imaging transmissions are focussed into an image scan plane, and (ii) receive reflections of the ultrasound imaging transmissions for generating a two-dimensional anatomical image corresponding to the image scan plane; and wherein the second set of localisation transducer elements are configured to produce ultrasound localisation transmissions into the human body for locating the medical instrument with respect to the two-dimensional anatomical image, wherein the ultrasound localisation transmissions extend outside the image scan plane, such that at least four localisation transducer elements from said second set are spaced from one another in a direction perpendicular to the image scan plane so as to be arranged at four or more different offsets from the image scan plane; and
a sensor console for receiving signals from a transducer that correspond to the localisation transmissions;
wherein the ultrasound system is configured to process the received signals to determine the location of the medical instrument within the human body relative to the ultrasound probe based on the received signals.

US Pat. No. 9,861,276

SUPRA-THRESHOLD TEST AND A SUB-PIXEL STRATEGY FOR USE IN MEASUREMENTS ACROSS THE FIELD OF VISION

UCL BUSINESS PLC, London...

1. Apparatus for performing a supra-threshold test at a set of multiple locations spread across a visual field of a subject,
said apparatus comprising:
a processor;
a memory; and
a display mechanism;
said apparatus being configured to:
for each given location in the set of locations, define a cluster of multiple locations in the set of locations which are
associated with said given location according to respective correlations between said given location and other locations in
the set of locations, wherein the cluster is defined based on paths of optic nerve fibre bundles across the visual field;

present a stimulus at each location in the set of locations and obtain a respective result for each location indicating whether
or not the stimulus was seen by the subject at that location;

estimate, for each given location in the set of locations, a probability of true damage (PTD) based on combining the results
obtained from the multiple locations of the cluster associated with said given location;

determine, for each given location in the set of locations, whether the probability of true damage is between an upper threshold
T1 and a lower threshold T2, such that T1>PTD>T2, and if so, select said given location for presentation of a further stimulus;

present a further stimulus at each selected given location in accordance with said determination and update the estimated
PTD for the each selected given location; and

output a binary map indicating a pass or fail at each of said set of locations as a result of the supra-threshold test, wherein
a given location is marked as failed if PTD>T1.

US Pat. No. 9,993,581

ENGINEERED NEURAL TISSUE

UCL Business PLC, (GB)

1. A method for producing an engineered tissue scaffold for neural repair, the method comprising:i) providing a cell guide comprising a hydrogel matrix seeded with neural stem cells obtained from a stable stem cell line, or with differentiated cells obtained from said stable stem cell line to form a seeded hydrogel matrix, the seeded hydrogel matrix being tethered at opposed first and second ends to a frame;
ii) incubating the seeded hydrogel matrix in culture medium, whereby the neural stem cells or the differentiated cells generate tension within the seeded hydrogel matrix, such that the cells self-align within the seeded hydrogel matrix; and
iii) removing liquid from the seeded hydrogel matrix in order to at least partially dehydrate the seeded hydrogel matrix to form a sheet while retaining cells within the seeded hydrogel matrix; thereby providing an engineered tissue scaffold.

US Pat. No. 9,633,108

METHOD AND SYSTEM FOR ANOMALY DETECTION IN DATA SETS

UCL BUSINESS PLC, London...

1. A method of operation of an apparatus for identifying anomalous data in a test data set, wherein the test data set is a
test image comprising a plurality of test pixels or voxels as test data points, the method comprising:
receiving input, by the apparatus, of at least one standard image comprising a plurality of standard pixels or voxels;
storing, by the apparatus, one or more standard data sets of a plurality of standard data cases, each standard data case containing
one or more standard data points representing normal, non-anomalous, data, wherein each standard data case is a corresponding
standard image, of the at least one standard image, comprising a corresponding plurality of standard pixels or voxels as standard
data points;

establishing a spatial correspondence between test data points of the test data set and respective corresponding standard
data points in the one or more standard data sets of the plurality of standard data cases, wherein the establishing the spatial
correspondence comprises spatially aligning the test image in co-registration with the at least one standard image;

calculating a first average similarity distance measure between (a) and (b), where (a) includes one or more test data points
in the test data set, and (b) includes one or more of the nearest neighboring corresponding standard data points in at least
two of the plurality of standard data cases;

determining a second average similarity distance measure between the nearest neighboring corresponding standard data points
in at least two of the plurality of standard data cases;

calculating a normalized similarity distance measure relating to the one or more test data points using a mathematical function,
wherein at least the first and second average similarity distance measures are inputs to the mathematical function; and

identifying a test data point as anomalous in dependence on a value of the calculated normalized similarity distance measure
for the test data point.

US Pat. No. 9,341,919

METHODS AND APPARATUS FOR CONTROLING DRIVE FREQUENCIES OF ACOUSTO-OPTIC DEFLECTORS

UCL BUSINESS PLC, London...

1. A method of configuring an acousto-optic lens for manipulating a beam of electromagnetic radiation so as to be deflected
and focused toward a desired location in space, said acousto-optic lens comprising at least a first acousto-optic deflector
driven by a first drive frequency and a second acousto-optic deflector driven by a second drive frequency, said method comprising:
for each of a plurality of possible locations in space, separately storing data related to a preferred frequency pair, wherein
a preferred frequency pair for a first one of said possible locations in space consists of a first preferred drive frequency
for said first acousto-optic deflector and a second preferred drive frequency for said second acousto-optic deflector, said
preferred frequency pair being such that if said first and second preferred drive frequencies of said pair were applied at
the same time to said respective first and second acousto-optic deflectors, said beam of electromagnetic radiation would be
deflected toward said first one of said possible locations in space;

consulting said data to determine a preferred frequency pair based on said desired location in space;
determining first and second drive frequencies as a result of said consulting step.
US Pat. No. 10,172,886

CELL

UCL BUSINESS PLC, London...

1. A T cell or natural killer (NK) cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising:(i) an antigen-binding domain;
(ii) a spacer
(iii) a trans-membrane domain; and
(iv) an endodomain
wherein the antigen binding domains of the first and second CARs bind to different antigens,
wherein the spacer of the first CAR is different from the spacer of the second CAR such that when both first and second CARs bind their target antigen, the difference in spacer dimensions results in spatial separation of the activating and inhibitory CARs to different parts of the membrane,
wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain, and
wherein the ligation-off inhibitory endodomain comprises a CD148 or CD45 tyrosine phosphatase domain.

US Pat. No. 10,118,155

METHOD OF METALLIC CLUSTERS FABRICATION WITH DESIRED SIZE USING SCANNING TUNNELING MICROSCOPY TIP INDUCED REACTIONS

SABIC Global Technologies...

1. A method of transferring a single metal atom from a first location to a second location on the surface of a metal oxide, the method comprising:(a) obtaining a material having metal atoms deposited on the surface of a metal oxide, wherein a first metal atom is deposited on a first oxygen atom vacancy of the metal oxide; and
(b) transferring the first metal atom on the first oxygen atom vacancy to a second location on the metal oxide by applying a voltage to the first metal atom,
wherein the second location is a second metal atom on a second oxygen atom vacancy of the metal oxide, and wherein the first and second metal atoms form a first metal atom-second metal atom species, or
wherein the second location is a metal atom of the metal oxide, and wherein the first metal atom and the metal atom of the metal oxide forms a first metal atom-metal atom of the metal oxide species.

US Pat. No. 9,793,686

SEMICONDUCTOR DEVICE AND FABRICATION METHOD

UCL Business PLC, London...

1. A semiconductor laser device comprising:
a silicon substrate;
an epilayer formed on the substrate;
a dot-in-well (DWELL) structure comprising multiple layers, each of the multiple layers comprising GaAs and an InGaAs alloy;
and

at least one layer of III-V compound, other than GaN, on the epilayer, wherein the epilayer comprises a compound of the formula:
Al1?x[X]xAs

wherein:
X is at least one group III element other than Al;
x is greater than or equal to 0; and
x is less than or equal to 0.5.
US Pat. No. 9,764,045

OPTIMISED CODING SEQUENCE AND PROMOTER

UCL BUSINESS PLC, London...

1. A vector comprising a promoter, wherein the promoter comprises the nucleotide sequence of SEQ ID NO: 3.
US Pat. No. 9,579,318

HISTAMINE 4 RECEPTOR PARTIAL AGONISTS, INVERSE AGONISTS OR ANTAGONISTS FOR USE IN TREATING NON-AUTOIMMUNE UVEITIS

UCL BUSINESS PLC, London...

1. A method of treating non-autoimmune uveitis, the method comprising administering an effective amount of a compound which
is a histamine 4 receptor antagonist, partial agonist or inverse agonist to a subject having non-autoimmune uveitis.

US Pat. No. 9,630,019

APPARATUS FOR PERFORMING DEEP BRAIN STIMULATION WITH AN ELECTRIC FIELD

UCL BUSINESS PLC, London...

1. An apparatus for performing deep brain stimulation with an electromagnetic field, the apparatus including an electrode
assembly having multiple electrodes and a phased array system for driving the electrodes to generate the electromagnetic field,
wherein the phased array system generates a pulsed signal for supply to the multiple electrodes, wherein the timing of the
pulsed signal is staggered between different electrodes to steer the electromagnetic field, and wherein the phased array system
is controllable such that the apparatus can vary a phase shift between adjacent electrodes from zero up to a predetermined
maximum.
US Pat. No. 9,566,257

COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE FOR TREATING HEPATIC ENCEPHALOPATHY

UCL Business PLC, London...

1. A pharmaceutical composition comprising ornithine or a physiologically acceptable salt thereof and at least one of phenylacetate
or phenylbutyrate or a physiologically acceptable salt thereof, wherein the composition comprises no other amino acid, wherein
the ornithine and at least one of phenylacetate or phenylbutyrate are in a weight ratio from 2:1 to 1:2, wherein the composition
is formulated for oral administration.

US Pat. No. 10,288,725

APPARATUS AND METHOD FOR PERFORMING PASSIVE SENSING

UCL Business PLC, London...

1. A method of performing passive sensing using wireless digital communications, wherein said wireless digital communications are frame-based with a predefined frame structure, and wherein said wireless digital communications are Wi-Fi communications from a wireless access point or WiMAX or LTE communications, said method comprising:receiving a reference signal into a reference channel, wherein said reference signal comprises a direct version of a radio frequency transmission as part of said wireless digital communications;
receiving a surveillance signal into a surveillance channel;
detecting and extracting portions of the reference signal corresponding to data transmissions based on said predefined frame structure;
extracting portions of the surveillance signal corresponding to the extracted portions of the reference signal;
performing a cross-correlation on the extracted portions of the reference signal and the surveillance signal to determine a range-Doppler surface;
and providing a real-time display of said range-Doppler surface and/or of information derived therefrom;
wherein the wireless digital communications comprise durations of active burst interspersed in the time domain with durations of idle bursts, and said method further comprises identifying and discarding from the reference signal the durations of the idle bursts prior to detecting and extracting portions of the reference signal corresponding to data transmissions based on said predefined frame structure.
US Pat. No. 10,093,716

METHODS FOR TREATING CANCER

UCL BUSINESS PLC, London...

1. A method for treating an individual with a Kirsten rat sarcoma viral oncogene homologue (KRAS)-mutated cancer, or a cancer in which Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) is inhibited independently of KRAS mutation, the method comprising administering to the individual a therapeutically-effective amount of an agent selected from the group consisting of:(i) an agent that binds to and neutralises TNF-related apoptosis-inducing ligand (TRAIL), and
(ii) an agent that binds to and neutralises TRAIL-receptor 2 (TRAIL-R2).
US Pat. No. 10,376,518

METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

UCL BUSINESS PLC, London...

1. A method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject:(i) a first agent which inhibits p38 phosphorylation; and
(ii) a second agent which is an anti-CD3 antibody;
wherein the subject is a non-responder to anti-CD3 therapy alone, showing no significant increase in FOXP3 expression on CD8+ T cells following anti-CD3 stimulation, and wherein the first agent is administered to the subject followed by the second agent or the two agents are administered simultaneously.
US Pat. No. 10,358,485

ANTI-TAU ANTIBODIES AND USES THEREOF

UCL Business PLC, London...

1. A monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds a human Tau, the antibody comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), and a heavy chain complementarity determining region 3 (HCDR3) as set forth in SEQ ID NO: 402 and a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3) as set forth in SEQ ID NO: 572.
US Pat. No. 10,174,099

CELL

UCL BUSINESS PLC, London...

1. A method for treating a cancerous disease, which comprises the step of administering a pharmaceutical composition which comprises a plurality of T cells or natural killer cells to a subject with a cancerous disease characterized by cancer cells that express CD19, wherein the T cells or natural killer cells express a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises:a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:CDR1—SYWMN (SEQ ID NO: 15),CDR2—QIWPGDGDTNYNGKFK (SEQ ID NO: 16), andCDR3—RETTTVGRYYYAMDY (SEQ ID NO: 17); andb) a light chain variable region (VL) having CDRs with the following sequences:CDR1—KASQSVDYDGDSYLN (SEQ ID NO: 18),CDR2—DASNLVS (SEQ ID NO: 19), andCDR3—QQSTEDPWT (SEQ ID NO: 20),wherein the VH domain has the sequence of SEQ ID NO: 24, or the VL domain has the sequence of SEQ ID NO: 26 or SEQ ID NO: 40.

US Pat. No. 10,087,068

STRESS RELIEVED MICROFABRICATED CANTILEVER

UCL Business PLC, London...

1. A micromechanical device having a microfabricated cantilever, a functional layer, and one or more metallic stress relief layers between the functional layer and the micromechanical device microfabricated cantilever, wherein the elastic modulus and thickness of each of the one or more metallic stress relief layers are configured to provide stress relief such that the microfabricated cantilever does not bend, and the thickness of the one or more layers is configured to by matching a degree of bending caused by the functional layer when the one or more metallic stress relief layers are not present.
US Pat. No. 9,840,720

MATERIALS AND METHODS RELATING TO PACKAGING CELL LINES

UCL Business PLC, London...

1. A method for producing a cell which constitutively expresses lentiviral gag and pol proteins, comprising the steps of
(i) providing a target cell comprising a single copy per cell of an exogenous nucleic acid construct integrated into a transcriptionally
active chromosomal locus in the cell genome, wherein the integrated nucleic acid construct is a retroviral provirus having
a 5? long terminal repeat (LTR) comprising a U3 and R-region, a 3? LTR comprising a U3 and R-region, said construct comprising
a first and a second mutant LoxP recombinase target site positioned so as to define a target construct between them; wherein
the first mutant LoxP recombinase target site is between the U3 and R-region in the 5? LTR and the second recombinase target
site is between the U3 and the R-region in the 3? LTR, thereby defining the target construct;

(ii) introducing into said cell an expression cassette comprising and nucleic acid encoding a promoterless selectable marker
and lentiviral gag and pol coding sequences under the control of a constitutive promoter, said expression cassette having
a LoxP recombinase target site at both the 5? and 3? ends, said 5? and 3? recombinase target sites corresponding to the first
and second recombinase target sites in the integrated nucleic acid sequence respectively; and

(iii) introducing a Cre-recombinase into the target cell and propagating the cell for recombinase-mediated exchange (RMCE)
between the expression cassette and the target construct at their respective recombinase target sites, wherein the expression
cassette replaces the target construct contained within the integrated retroviral provirus between 5? LTR U3 and the 3? LTR
R regions, and wherein the expression cassette is integrated between a double mutant LoxP site downstream of the first 5?
LTR U3 region and a LoxP site upstream of the 3? LTR R-region; and

(iv) selecting the target cell which expresses the selectable marker under the control of the 5? U3 promoter upstream of the
double mutant LoxP site, said target cell also expressing gag and pol protein.

US Pat. No. 9,702,955

APPARATUS AND METHOD FOR CORRECTING SUSCEPTIBILITY ARTEFACTS IN A MAGNETIC RESONANCE IMAGE

UCL BUSINESS PLC, London...

1. A method of correcting susceptibility artefacts in an acquired magnetic resonance image comprising the steps of:
performing phase unwrapping for an acquired magnetic resonance (MR) image, including computing a confidence for the phase
unwrapping for each voxel of the acquired MR image;

generating a field map for the acquired magnetic resonance image from the unwrapped phase;
converting the field map to a deformation field; and
using the deformation field to initialise a non-rigid image registration of the acquired MR image against a reference image,
wherein the deformation field of the non-rigid registration is controlled to be smoother where said confidence is high.

US Pat. No. 10,406,131

TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES

UCL BUSINESS PLC, London...

1. A method of treating or delaying the onset or progression of a disease associated with hepatic stellate cell (HSC) activation, comprising administering an ammonia-lowering agent to a subject in need thereof, wherein the disease associated with HSC activation is non-alcoholic fatty liver disease (NAFLD), liver cancer, or fibrotic condition.
US Pat. No. 10,124,041

METHODS OF DELIVERING FACTOR VIII ENCODING NUCLEIC ACID SEQUENCES

UCL BUSINESS PLC, London...

1. A method for administering to a subject a nucleic acid molecule encoding a Factor VIII protein, comprising:intravenously administering to the subject a nucleic acid molecule encoding a Factor VIII protein, wherein the Factor VIII protein B domain comprises a spacer that is replaced and wherein the B domain comprises the amino acid sequence set forth in SEQ ID NO:4.
US Pat. No. 10,457,730

CHIMERIC ANTIGEN RECEPTOR (CAR) COMPRISING A CD19-BINDING DOMAIN

UCL BUSINESS PLC, London...


US Pat. No. 10,309,027

METHOD FOR PRODUCING DISPERSIONS OF NANOSHEETS

UCL Business PLC, London...

1. A method for producing a thermodynamically stable solution of nanosheets, comprising the step of contacting an intercalated layered material with a polar aprotic solvent to produce a solution of nanosheets, wherein the intercalated layered material is prepared from a layered material selected from the group consisting of a transition metal dichalcogenide, a transition metal monochalcogenide, a transition metal trichalcogenide, a transition metal oxide, a metal halide, an oxychalcogenide, an oxypnictide, an oxyhalide of a transition metal, a trioxide, a perovskite, a niobate, a ruthenate, a layered III-VI semiconductor, black phosphorous and a V-VI layered compound.
US Pat. No. 10,709,796

OPTIMISED CODING SEQUENCE AND PROMOTER

UCL BUSINESS PLC, London...

1. A recombinant adeno-associated virus (AAV) particle comprising a heterologous nucleic acid sequence and a liver-specific promoter that is operably linked to and drives expression of said heterologous nucleic acid sequence, wherein said promoter has at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:3 and is less than 350 base pairs in length.

US Pat. No. 10,118,892

COMPOUNDS AND THEIR SYNTHESIS

UCL BUSINESS PLC, London...

1. A sulfonium salt according to formula (I):whereinR1 and R2 are joined together to form, together with the sulfur atom, an optionally substituted dibenzothiophene ring;
W is an optionally substituted aryl group or an optionally substituted heteroaryl group;
R3 is a moiety comprising at least one basic group, wherein the basic group of R3 is a Brønsted base and/or Lewis base and is selected from a primary amine, secondary amine, tertiary amine, amidine, guanidine, enamine, hydrazine, hydrazone, hydroxylamine, imine, an N-containing-heterocyclyl group, and an N-containing-heteroaryl group;
X is an anionic species; and
n is an integer selected from 1 to 5,
wherein W—R3 is a group capable of binding to a biological target and/or is a biologically active agent,
wherein the aryl group of the optionally substituted aryl group of W is a C6-C16 aryl group, and
wherein the heteroaryl group of the optionally substituted heteroaryl group of W is a 5-6 membered monocyclic or 8-16 membered fused bicyclic or tricyclic heteroaryl group.
US Pat. No. 10,098,911

CHIMERIC PROTEIN

UCL BUSINESS PLC, London...

1. A method for treating a cancer in a subject which comprises the step of administering a cell to the subject, which cell:(i) expresses a T-cell receptor (TCR) or chimeric antigen receptor (CAR) and
(ii) comprises a chimeric protein having the formula:
Ht1-Ht2-Casp
wherein Casp is a caspase domain,
Ht1 is a first heterodimerization domain, and
Ht2 is a second heterodimerization domain;wherein one heterodimerization domain comprises an FK506-binding protein (FKBP) and the other heterodimerization domain comprises an FRB domain of mTOR;and wherein, in the presence of rapamycin or a rapamycin analog, an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains.

US Pat. No. 10,010,623

LYSOSOME-CLEAVABLE LINKER

UCL Business PLC, (GB)

1. A compound of formula (Ia), (Ib) or (Ic)
wherein:
R1 is an antibody or antibody fragment, wherein said antibody or antibody fragment is capable of binding to an antigen;
R2 is a therapeutically active agent;
R3 is a linker moiety or a bond; and
R4 is a hydrogen or halogen atom or a C1-20 alkyl, C2-20 alkenyl or C2-20 alkynyl group, which group is unsubstituted or substituted by one or more substituents selected from halogen atoms and sulfonic acid groups, and in which (a) 0, 1 or 2 carbon atoms are replaced by groups selected from C6-10 arylene, 5- to 10-membered heteroarylene, C3-7 carbocyclylene and 5- to 10-membered heterocyclylene groups, and (b) 0, 1 or 2 —CH2— groups are replaced by groups selected from —O—, —S—, —S—S—, —C(O)— and —N(C1-6 alkyl)- groups, wherein:
(i) said arylene, heteroarylene, carbocyclylene and heterocyclylene groups are unsubstituted or substituted by one or more substituents selected from halogen atoms and C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthiol, —N(C1-6 alkyl)(C1-6 alkyl), nitro and sulfonic acid groups; and
(ii) 0, 1 or 2 carbon atoms in said carbocyclylene and heterocyclylene groups are replaced by —C(O)— groups;
R1 being linked to the 2-position of the moiety of formula (Ia) via a first sulfur atom attached to the 2-position of the moiety of formula (Ia); R1 being linked to the 3-position of the moiety of formula (Ib) via a first sulfur atom attached to the 3-position of the moiety of formula (Ib); and R1 being linked to the 2-position of the moiety of formula (Ic) via a first sulfur atom attached to the 2-position of the moiety of formula (Ic) and R1 being linked to the 3-position of the moiety of formula (Ic) via a second sulfur atom attached to the 3-position of the moiety of formula (Ic).

US Pat. No. 9,952,163

CODED-APERTURE X-RAY IMAGING

UCL BUSINESS PLC, London...

1. A method of X-ray imaging, comprising:passing an X-ray beam through an absorbing pre-sample mask with one or more apertures spaced apart in the x direction;
passing the X-ray beam through a sample;
detecting the X-rays using a spatially resolving detector representing a detector mask having one or more apertures spaced apart in the x-direction at a corresponding spacing to the apertures in the pre-sample mask, to provide one or more images Ii, wherein i is the number of images with the relative position of the pre-sample mask and detector mask at respective position or positions xi, wherein i is the number of positions and
obtaining a dark field image of the sample by calculating the dark field image from the captured image or images Ii at respective positions xi using a formulation representing the image intensity as a function of scattering, transmission and refraction, wherein obtaining a dark field image comprises solving the equationfrom the captured image or images Ii at respective positions xi to obtain the dark field image of the sample;where * denotes convolution, I0 is the beam intensity passing through the sample aperture, the illumination function L(x) describes how the detected beam intensity changes as a function of the relative displacement x between the pre-sample and the detector mask, in the absence of the sample, t represents the transmission of the sample, ?xR represents the refraction induced by the sample and O(x) describes the scattering of the sample, represented in the dark field image.
US Pat. No. 10,413,598

FACTOR IX GENE THERAPY

UCL Business PLC, London...

1. A vector for expressing a protein, the vector comprising:a promoter operably linked to a polynucleotide encoding the protein;
wherein the promoter has at least 90% sequence identity to SEQ ID NO: 4.
US Pat. No. 10,160,794

CHIMERIC ANTIGEN RECEPTOR

UCL BUSINESS PLC, London...

1. A method for the treatment of plasma cell cancer selected from the group consisting of plasmacytoma, plasma cell leukemia, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, solitary hone plasmacytoma, extramedullary plasmacytoma, osteosclerotic myeloma, heavy chain diseases, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma in a subject, comprising:administering to the subject a T cell which expresses a chimeric antigen receptor (CAR), wherein the CAR comprises:
a truncated proliferation-inducing ligand (APRIL) that
(a) binds B cell maturation antigen (BCMA) and
(b) binds transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)
(ii) a spacer domain,
(iii) a transmembrane domain; and
(iv) an intracellular T signaling domain,
wherein administration of said T-cell results in a reduction in cancer cells in the subject.
US Pat. No. 10,039,735

TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES

UCL BUSINESS PLC, London...

1. A method of treating or delaying the onset or progression of a disease associated with hepatic stellate cell (HSC) activation, comprising administering an ammonia-lowering agent to a subject in need thereof, wherein the ammonia-lowering agent comprises ornithine phenylacetate.
US Pat. No. 9,937,133

TREATMENT OF FIBROSIS

UCL Business PLC, London...

1. A method for treating or preventing mucous membrane pemphigoid (MMP) in a patient in need thereof, the method comprising administering to said patient an aldehyde dehydrogenase inhibitor, wherein the aldehyde dehydrogenase inhibitor is tetraethylthioperoxydicarbonic diamide (disulfiram) or 4-(diethylamino)benzaldehyde (DEAB).
US Pat. No. 10,314,924

RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA

UCL Business PLC, London...

1. A method of treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to an eye of the subject a nucleic acid comprising a viral vector comprising an abbreviated human RPGR cDNA, wherein the abbreviated human RPGR cDNA encodes a protein comprising SEQ ID NO:2.
US Pat. No. 10,184,136

RETROVIRAL VECTORS

UCL Business PLC, London...

1. A retroviral vector comprising a primer binding site, a long terminal repeat, a promoter, and an RNA packaging sequence, wherein the RNA packaging sequence is located 3? of the long terminal repeat and no long terminal repeat is located 3? of the RNA packaging sequence such that reverse transcription initiated at the primer binding site does not lead to reverse transcription of the RNA packaging sequence into vector DNA in a target cell, wherein the RNA packaging sequence comprises an RNA packaging signal (?) and a Rev Response Element (RRE).
US Pat. No. 10,098,926

CELL

UCL BUSINESS PLC, London...


 wherein cancer cells of the cancerous disease express CD22.
US Pat. No. 10,098,960

POLYMER CONJUGATE

UCL BUSINESS PLC, London...

1. A conjugate of a domain I ?2GP1 polypeptide with a water-soluble polymer, wherein the polymer is bound via two cysteine residues derived from a disulfide bridge in the domain I ?2GP1 polypeptide, and wherein the domain I ?2GP1 polypeptide comprises an amino acid sequence selected from the group consisting of: the amino acid sequence of SEQ ID NO: 2 and analogues thereof, and the amino acid sequence of SEQ ID NO: 3 and analogues thereof.
US Pat. No. 10,286,092

DETECTING A THERAPEUTIC CELL

UCL Business PLC, London...

1. A method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject comprising the therapeutic cell, which method comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined by binding of the DAT tracer to the DAT on the therapeutic cell, and wherein the therapeutic cell is an immune effector cell engineered to express a DAT protein prior to administration of said cell to the subject.
US Pat. No. 10,426,845

DIABETES GENE THERAPY

UCL Business PLC, London...

1. A nucleic acid molecule comprising a nucleotide sequence encoding a functional preproinsulin protein wherein the nucleotide sequence has at least 89% identity to the sequence of SEQ ID NO. 1.

US Pat. No. 10,494,404

QUINOLINIUM CONJUGATES OF CYCLOSPORIN

UCL Business PLC, London...

1. A cyclosporin conjugate which is a compound of formula (I) or a pharmaceutically acceptable salt thereof:in which:A represents

B represents methyl or ethyl,
R2 represents ethyl or isopropyl,
R4 represents —CH2CH(CH3)CH3, —CH2CH(CH3)CH2CH3, —CH(CH3)CH3 or —CH(CH3)CH2CH3,
either (a) one of R1 and R1* represents -L1Z1 and the other represents hydrogen, and R3 represents hydrogen, C1-C3 alkyl or C2-C4 alkenyl, (b) one of R1 and R1* represents methyl and the other represents hydrogen, and R3 represents -L3Z3, or (c) one of R1 and R1* represents -L1Z1 and the other represents hydrogen, and R3 represents -L3Z3,
L1 and L3 independently represent a C1-C6 alkylene moiety, a C2-C6 alkenylene moiety or a —(CH2CH2O)n(CH2)m— moiety in which n represents 1 to 3 and m represents 0 to 2, and
Z1 and Z3 independently represent a moiety of formula (II*):

in which Q1* to Q7* independently represent a hydrogen atom, a C1-C6 haloalkyl group, a —OR? group, or a —NR?R? group, wherein R? and R? are the same or different and represent hydrogen or a C1-C6 alkyl group, and wherein four to seven of Q1* to Q7* represent hydrogen.

US Pat. No. 11,109,962

BIOPROSTHETIC HEART VALVE

UCL Business PLC, London...


1. A method for fabricating a bioprosthetic heart valve, the method comprising:providing: a sheet of biological tissue, a sheet of a biocompatible material, and a stent, the stent having an upstream edge and a downstream edge as well as an inner surface and an outer surface;
attaching the biological tissue to the biocompatible material along a suture line;
folding the biocompatible material to form a tubular structure with the attached biological tissue located on an inner surface of the tubular structure, the biological tissue forming leaflets of the heart valve;
securing the stent around an outer surface of the tubular structure such that the tubular structure extends in an upstream direction beyond the upstream edge of the stent and in a downstream direction beyond the downstream edge of the stent;
cutting at least one region of the biocompatible material at a downstream end of the tubular structure;
folding the biocompatible material at the at least one cut region away from the biological tissue and around the downstream edge of the stent and securing it to the outer surface of the stent; and
folding and attaching the biocompatible material at an upstream end of the tubular structure around the upstream edge of the stent so that the inner and outer surfaces of the stent are covered with no more than a single layer of the biocompatible material.

US Pat. No. 10,433,274

APPARATUS AND METHOD FOR CALIBRATING A WIRELESS ACCESS POINT COMPRISING AN ARRAY OF MULTIPLE ANTENNAS

UCL Business PLC, London...

1. A method of calibrating a wireless access point comprising an array of multiple (m) antennas denoted Ai (i=1 . . . m), each antenna having a respective internal phase offset ?i, said method comprising:receiving a signal from at least one transmitter located at a substantially known bearing from the wireless access point; and
determining an estimated value for each internal phase offset ?i such that an angle of arrival (AoA) spectrum calculated for the received signal on the basis of said estimated values matches the known bearing, wherein said AoA spectrum is calculated by treating said multiple antennas as a phased array;
wherein said method further comprises computing a correlation function for the calculated AoA spectrum against the known bearing to provide a measure of whether or not a match is present, wherein said correlation function is selected to be: (i) higher if the AoA spectrum contains a peak in the direction of the known bearing; (ii) lower if there are peaks in directions other than said known bearing; and (iii) lower if the peak in the direction of the known bearing in is low compared to a noise floor for the AoA spectrum.
US Pat. No. 10,414,803

CAPSID

UCL BUSINESS PLC, London...

1. An AAV capsid protein comprising an amino acid sequencei) having the sequence of SEQ ID NO: 3; or
ii) having at least 99% identity to SEQ ID NO: 3 and is a hybrid capsid comprising regions of the AAV3B and AAV8 capsids.

US Pat. No. 10,357,358

HEART VALVE PROSTHESIS

UCL BUSINESS PLC, London...

1. A heart valve prosthesis comprising:a support structure comprising a framework deformable between an expanded state and a compressed state and vice versa, said support structure having a radial dimension when in the expanded state and a smaller radial dimension when in the compressed state, said support structure comprising smoothly curved ribs; and
a flow-control structure, supported by the support structure, for permitting blood flow downstream in a first direction, defining an axial direction of the prosthesis, and for restricting blood flow in an upstream direction opposite to the first direction,
wherein the flow-control structure comprises at least three leaflets each having a radially outer edge so as to define a profile, each leaflet having an associated smoothly curved rib,
each associated smoothly curved rib having a curve to match the profile of the radially outer edge of their associated leaflet and to which each said individual smoothly curved rib is attached,
wherein the support structure further comprises a first set of petal-like portions that protrude beyond the flow-control structure axially in the upstream direction in which the flow-control structure restricts blood flow opposite to the first direction in which the flow-control structure permits blood flow, and protrude radially further than the flow-control structure,
wherein at least one end of the support structure comprises a plurality of apexes of the framework,
wherein the support structure is collapsible from the fully expanded state into the compressed state by pulling on the apexes, to enable it to be drawn into a sheath in the compressed state, the sheath having an inner radial dimension smaller than the radial dimension of the support structure in the expanded state, and
wherein the smoothly curved ribs are a single bent wire.
US Pat. No. 11,040,101

NANOPARTICLES FOR CANCER THERAPY AND DIAGNOSIS

UCL Business PLC, London...


1. A nanoparticle for use in delivering an amphiphilic or hydrophobic sensitizer to a solid tumour target,wherein exposure of said sensitizer to either NIR or ultrasound causes ablation of said tumor,
wherein the nanoparticle contains, and binds non-covalently to, the sensitizer,
wherein the nanoparticle is composed of a polymer or co-polymer of at least 30 monomers linked by peptide bonds, wherein the polymer or co-polymer comprises one or both of monomers M1 and M2,wherein M1 is glutamic acid,
wherein M2 is glutamic acid wherein a carboxyl group is derivatised with a pendant group,wherein the pendant group is selected from: a lipid; a group comprising an aromatic ring; a positively-charged group; an aliphatic group;


wherein the polymer or co-polymer optionally further comprises monomer M3 which is different to M1 and M2,wherein M3 is either a naturally occurring amino acid having a side-chain group,
or M3 is a synthetic monomer having a side chain groupwherein the side chain group is selected from: a positively charged group; a polar uncharged group; a hydrophobic group,


wherein the polymer or co-polymer comprises at least M2 or M3, and
whereby the pendant groups and/or side chains of the polymer of co-polymer interact non-covalently with the sensitizer.

US Pat. No. 10,963,741

CONTROL DEVICE, SYSTEM AND METHOD FOR DETERMINING THE PERCEPTUAL LOAD OF A VISUAL AND DYNAMIC DRIVING SCENE

TOYOTA MOTOR EUROPE, Bru...

1. A control device for a vehicle for determining a perceptual load of a visual and dynamic driving scene,the control device being configured to:
receive a sensor output of a sensor, the sensor sensing the visual driving scene,
extract a set of scene features from the sensor output, the set of scene features representing static and/or dynamic information of the visual driving scene, and
determine the perceptual load of the set of extracted scene features based on a predetermined load model, wherein
the load model is predetermined based on reference video scenes each being labelled with a load value.
US Pat. No. 10,688,221

HUMAN LIVER SCAFFOLDS

UCL BUSINESS PLC, London...

1. A method of producing a decellularized human liver scaffold comprising(i) providing healthy or pathological human liver tissue comprising a whole liver or a functional unit thereof,
(ii) mechanically damaging the cells in the tissue,
(iii) subjecting the cells in the tissue to osmotic stress by exposing the tissue to a hypotonic reagent or hypertonic reagent,
(iv) exposing the tissue to a protease and/or DNAase, and
(v) exposing the tissue to a detergent, and
(vi) repeating steps (iii) to (v) in the following sequence by perfusion through the liver tissue: (iii), (iv), (iii), (iv), (v), [(iii), (v)]n, optionally [(iii), or (iv)], [(iii), (v)]n, where n is independently 1 to 25;
thereby producing a decellularized human liver scaffold,
wherein the human liver tissue is subjected to flow shear stress generated by perfusing the human liver tissue in a retrograde direction with the hypotonic reagent, hypertonic reagent, protease and/or DNAase, and detergent during steps (iii) to (vi) at a perfusion rate which increases from an initial value of 0.1-1.99 ml/min/gram of tissue and stabilizes to a target value of 2-20 ml/min/gram of tissue.
US Pat. No. 11,103,596

FABRY DISEASE GENE THERAPY

UCL BUSINESS PLC, London...


1. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having ?-galactosidase A activity wherein the nucleotide sequence has at least 91% identity to the nucleotide sequence of SEQ ID NO: 1.
US Pat. No. 11,069,445

MEDICAL DIAGNOSIS ASSISTANCE METHOD

SORBONNE UNIVERSITE, Par...


1. A device-implemented method for assistance with the establishment of a diagnosis of a patient, comprising:providing a device that incorporates a computerized knowledge database (10) of a medical ontology (12) that includes a first list (121) of signs (Si) forming a “sign” class, a list (122) of pathological states (Dj) forming a “pathological state” class, a first set (124) of logical relationships between the signs and the pathological states, each logical relationship of said first set (124) establishing a correlative link between a sign and a pathological state, a second list (123) of technical methods for acquiring medical images (Mk) forming an “imaging” class, each of said technical methods for acquiring medical images (Mk) defining a type of technology for acquisition of medical images and a positioning of the medical image on the patient, and a third set (126) of logical relationships between the signs and the technical methods for acquiring medical images (Mk), each logical relationship of said third set (126) defining a technical method for acquiring a medical image that makes possible an observation of a sign;
receiving, at the device from an operator of the device, one or more identified signs;
searching (503), carried out by the device, for potential pathological states, in which all of the pathological states linked by a correlative link to at least one of the identified signs are sought in the pathological state class by means of the first set (124) of logical relationships, said pathological states forming the potential pathological states;
identifying (504), carried out by the device, potential signs in which, for each potential pathological state, all of the signs linked by a correlative link to said potential pathological state are identified in the sign class by means of the first set (124) of logical relationships, said signs forming the potential signs; and
identifying (505), carried out by the device, technical methods for acquisition of interest, in which for each potential sign, all of the technical methods for acquiring medical images that make possible to observe said potential sign are identified in the imaging class by means of the third set (126) of logical relationships, said technical methods for acquiring medical images forming the technical methods for acquisition of interest.

US Pat. No. 11,049,267

APPARATUS, METHOD, AND SYSTEM FOR ALIGNMENT OF 3D DATASETS

UCL BUSINESS PLC, London...


1. An apparatus comprising:a 3D dataset acquisition unit, configured to:obtain from an imaging apparatus at a first position and orientation, a first 3D dataset of a first space at a first time, the first 3D dataset being a first point cloud in three dimensions, each point in the first point cloud representing a reading within the first space by the imaging apparatus; and
obtain from an imaging apparatus at a second position and orientation, a second 3D dataset of a second space at a second time, the second space and the first space overlapping, the second 3D dataset being a second point cloud in three dimensions, each point in the second point cloud representing a reading within the second space by the imaging apparatus;

a storage unit configured to store the first 3D dataset and the second 3D dataset as respective clouds of points in a common coordinate system; and
a rotational alignment processor configured to:transform the stored first point cloud into a first set of vectors, and transform the stored second point cloud into a second set of vectors, wherein each member of the first set of vectors and each member of the second set of vectors represents the respective point and neighbouring points;
find at which angle of rotation of the second set of vectors relative to the first set in one or more of three axes of rotation, defined in the common coordinate system, the greatest degree of matching between the angular distribution of the first set of vectors and the angular distribution of the second set of vectors is obtained, the degree of matching being measured to compare the angular distributions of the first and second sets of vectors; and either:output the angle of rotation about each of the one or more axis or axes of rotation for which the calculated degree of matching is greatest; or
rotate the second point cloud by the found angle of rotation about the respective one or more axes of rotation in the common coordinate system and output the rotated second point cloud in the common coordinate system;



whereinthe apparatus further comprises:
a translational alignment processor configured to:
for a line and a plane in the common coordinates system, wherein the line is at an angle to or normal to the plane:record the position, relative to an arbitrary origin, of a projection onto the line of each point among the first point cloud and store the recorded positions as a first 1-dimensional array, and/or store one or more properties or readings of each point at the respective recorded position as the first 1-dimensional array;
record the position, relative to an arbitrary origin, of a projection onto the plane of each point among the first point cloud, and store the recorded positions as a first 2-dimensional array, and/or store one or more properties or readings of each point at the respective recorded position as the first 2-dimensional array;
record the position, relative to the arbitrary origin, of the projection onto the line of each point among the rotated second point cloud, and store the recorded positions as a second 1-dimensional array, and/or store one or more properties or readings of each point at the respective recorded position as the second 1-dimensional array;
record the position, relative to an arbitrary origin, of a projection onto the plane of each point among the rotated second point cloud, and store the recorded positions as a second 2-dimensional array, and/or store one or more properties or readings of each point at the respective recorded position as the second 2-dimensional array;
find a translation along the line of the second 1-dimensional array relative to the first 1-dimensional array at which a greatest degree of matching between the first 1-dimensional array and the second 1-dimensional array is computed, and record the translation at which the greatest degree of matching is computed; and
find a translation, in the plane, of the second 2-dimensional array relative to the first 2-dimensional array at which a greatest degree of matching between the first 2-dimensional array and the second 2-dimensional array is computed, and record said translation;

output either:the first point cloud and the rotated second point cloud as a merged point cloud in the common coordinate system, with the rotated second point cloud translated along the line and in the plane in the common coordinates system by the respective recorded translation; and/or
a vector representation of the recorded translation along the line and in the plane, and a vector representation of the three axes of rotation and the respective found angles of rotation; and/or
the rotated second point cloud translated along the line and in the plane in the common coordinates system by the respective recorded translation.


US Pat. No. 10,898,366

WEARABLE GARMENT AND ITS USE IN PREVENTING STRETCH MARKS

STUFF OF LIFE LIMITED, M...

1. A method for preventing or reducing the likelihood of stretch marks on a subject, which comprises the subject wearing a band comprising,a first edge, a second edge, and
an inner surface between the first edge and the second edge,
wherein said inner surface has an array of tacky pads arranged on the inner surface and between said first edge and said second edge, wherein the tacky pads are arranged separately to one another, with spaces therebetween, such that they do not touch and such that it is not possible to draw a continuous straight line starting from said first edge and crossing said second edge only within the spaces between the tacky pads wherein the straight line does not cross at least one of said tacky pads, and wherein each of said tacky pads forms a friction-creating contact adapted to adhere to skin so that skin in contact with the tacky pads moves with the tacky pads and the tacky pads function to dissipate foci of stress in the skin, thereby inhibiting the formation of stretch marks; wherein the band is worn by a subject in the second or third trimester of pregnancy on an area at risk of developing stretch marks.